Isomorphic Labs in talks for ~$5B raise at ~$50B valuation
rohanpaul_ai · x · 2026-11-05
Bloomberg reports Isomorphic Labs, the Alphabet company spun out of Google DeepMind, is negotiating a roughly $5B raise at about $50B valuation—with no drug yet tested in humans. Its product is a drug-design engine built on AlphaFold 3 that predicts protein folding and molecule binding, letting chemists filter weak designs before synthesis. Critics note the $50B price rests on prediction accuracy and pharma partnerships, not proven clinical results.
Related event: Isomorphic Labs in Talks to Raise $5 Billion at $50 Billion Valuation(2 posts)→
More from Venture
- Cluely isn't an app studio: Roy Lee says a thesis was validated 4 months ago, staying quiet — Scobleizer · 2026-11-05
- tinyfool uses AI to study power users of his English reading app — wildly divergent data — tinyfool · 2026-11-05
- Basket of 19 neocloud stocks (NBIS, CRWV, IREN) now merely matches the S&P 500 after wiping out 100-point lead — tengyanAI · 2026-11-05
- Your first $10K AI client is in your phone: warm network beats cold outreach — aryanXmahajan · 2026-11-05
- Fireworks AI cofounder: training is now an economics play for AI apps — sophiamyang · 2026-11-05
- ACX November links: NVIDIA to buy Hugging Face for $12.9303B, Sentinel sees 25% AI exfiltration risk — Astral Codex Ten · 2026-11-05